CIRM Funded Clinical Trials

Clinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Hematologic Malignancies and Solid Tumors


Irving Weissman
Investigator:
CIRM Grant:
Award Value:
$12,726,396
Trial Sponsor:
Trial Stage: 
Phase 1
Trial Status: 
Recruiting
Targeted Enrollment:
96
ClinicalTrials.gov ID:
Details: 

CD47 is a cell surface protein that regulates phagocytosis mediated by macrophages by delivering a potent “don’t eat me” signal to phagocytic cells. Increased expression of CD47 on cancer and cancer stem cells is presumed to prevent their phagocytic elimination. Blocking of CD47 e.g., using an antibody to CD47,  enables phagocytosis of the cancer cells.

Goal: 

Safety. Dose range finding. Determination of MTD.

Status: 

Recruiting.